Globus Medical (GMED)
(Delayed Data from NYSE)
$72.05 USD
+2.37 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $72.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.05 USD
+2.37 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $72.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Zacks News
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits
by Zacks Equity Research
Select Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations.
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day
Omicron Hits Elective MedTechs, 3 Subsectors Likely to Thrive
by Urmimala Biswas
Here we discuss three major subsectors of MedTech and three constituent stocks, OPCH, GMED and OMCL for which the change in the scenario has opened up enormous growth prospects.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.
NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical
by Zacks Equity Research
NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.
Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.
Globus Medical (GMED) Q3 Earnings Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 11.11% and -0.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Progresses With ExcelsiusGPS in DBS
by Zacks Equity Research
According to Globus Medica (GMED), the clinical superiority of ExcelsiusGPS continues to be recognized by surgeons.
Here's Why You Should Retain Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.
Globus Medical (GMED) Up 4.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Globus Medical (GMED) Gets FDA Nod for Excelsius3D
by Zacks Equity Research
The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.
Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.
Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 24.44% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Globus Medical (GMED) Could Beat Earnings Estimates Again
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
Medical Products' Aug 4 Earnings Roster: MCK, ABC & More
by Trina Mukherjee
The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
4 Medical Device Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.
Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand
by Zacks Equity Research
Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.
Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.
NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.
Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
by Zacks Equity Research
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.